Citigroup’s Co-Diagnostics CODX Stock Holding History

Citigroup’s Portfolio CODX Stock Details CODX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2	Buy	+1	New	+$3	﹤0.01%	5826
2025 Q4	–	Sell	-49	Closed	-$501	–	6126
2025 Q3	$501	Sell	49 -130	-73%	-$1.21K	﹤0.01%	5707
2025 Q2	$1.51K	Buy	179 +169	+1,690%	+$1.58K	﹤0.01%	5378
2025 Q1	$91	Buy	+10	New	+$191	﹤0.01%	5439
2021 Q3	–	Sell	-3	Closed	-$1K	–	5824
2021 Q2	$1K	Sell	3 -71	-96%	-$18.3K	﹤0.01%	6024
2021 Q1	$21K	Sell	74 -129	-64%	-$51.5K	﹤0.01%	5210
2020 Q4	$57K	Buy	203 +34	+20%	+$12.6K	﹤0.01%	5942
2020 Q3	$69K	Sell	169 -212	-56%	-$109K	﹤0.01%	5370
2020 Q2	$221K	Buy	+381	New	+$174K	﹤0.01%	4942

Other funds holding CODX

PAG

Private Advisory Group Redmond, Washington $1.52B AUM 41.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SAM

Smartleaf Asset Management Boston, Massachusetts $2.77B AUM 22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

HWA

Heritage Wealth Advisors Richmond, Virginia $2.56B AUM 19.48% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Danske Bank Copenhagen K, Denmark $41.5B AUM 29.19% 1-Year Est. Return

Citigroup's CODX Position: Q1 2026 in Review

Citigroup opened a new position in Co-Diagnostics (CODX) in Q1 2026: 1 share worth $2. The stake represents ﹤0.01% of the portfolio and ranks #5826 among its holdings. This is a return to the name: Citigroup previously reported a position in CODX as recently as Q3 2025.

Citigroup first reported a position in CODX in Q2 2020 and has held it in 9 quarters since. The position peaked at $221K in Q2 2020. 14 funds tracked by Wall St. Rank hold CODX as of Q1 2026.

Citigroup held 1 share of Co-Diagnostics worth $2 as of Q1 2026.
Co-Diagnostics was a new Citigroup position in Q1 2026.
Co-Diagnostics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5826 holding.
Citigroup first reported a position in Co-Diagnostics in Q2 2020 and has held it in 9 quarters since.
Citigroup's Co-Diagnostics position peaked at $221K in Q2 2020.
14 funds tracked by Wall St. Rank held Co-Diagnostics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.